Citi Reiterates Buy Rating on Becton, Dickinson Post-Spinoff, Sets $233 Price Target

martes, 3 de febrero de 2026, 9:24 am ET1 min de lectura
BDX--

Citi has resumed coverage of Becton, Dickinson at buy, expecting faster growth post-spinoff of Biosciences & Diagnostic Solutions to Waters on Feb. 9. The bank has a $233 price target, representing a 15% upside. The spinoff is expected to allow BD to focus on its core medical technology business and potentially drive growth.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios